The biopharma firm added that they will continue testing on the drug in other conditions, such as Parkinson’s disease. The news has placed TORC firmly in penny stock territory, down 82.2% at $1.41, …
More Failed Drug Trial Sends TORC Into Penny Stock Territory Videos